Drug Profile
Fibrinogen/thrombin dry powder - Mallinckrodt
Alternative Names: Factor I/factor IIa; Factor IIa/factor I; Fibrocaps; Human fibrinogen/human thrombin; Human thrombin/human fibrinogen; PRO-0601; Raplixa; Thrombin/fibrinogenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ProFibrix
- Developer Mallinckrodt plc
- Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
- Mechanism of Action Fibrinogen replacements; Thrombin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Surgical blood loss
- Discontinued Soft tissue injuries
Most Recent Events
- 21 Nov 2019 Mallinckrodt terminates a phase II trial for Surgical blood loss (In children, In infants, In neonates, In adolescents) in USA due to non-safety device related issues (Topical) (NCT02117349)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Soft tissue injuries in Netherlands (Topical, Powder)
- 31 Dec 2018 Discontinued - Phase-II for Surgical blood loss (In adolescents, In children, In infants, In neonates) in USA (Topical)